Cardiotoxicity in patients receiving trastuzumab (Herceptin): Primary toxicity, synergistic or sequential stress, or surveillance artifact?

Seminars in Oncology

Volumn 26, Issue 4 SUPPL. 12, 1999, Pages 96-101

  Ewer, M S ^a   Gibbs, H R ^a   Swafford, J ^a   Benjamin, R S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; MONOCLONAL ANTIBODY; TRASTUZUMAB; UNCLASSIFIED DRUG;

ARTICLE; CARDIOMYOPATHY; CARDIOTOXICITY; CELL DIFFERENTIATION; CELL SURVIVAL; DRUG EFFECT; GROWTH INHIBITION; HEART MUSCLE BIOPSY; HUMAN; LUNG TOXICITY; ONCOGENE NEU; PRIORITY JOURNAL; STRESS; TUMOR GROWTH;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; HEART; HUMANS; RECEPTOR, ERBB-2;

EID: 0032874107     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)